domoxin

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 1-benzyl-1-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)hydrazine

| image = Domoxin.svg

| image_class = skin-invert-image

| CAS_number = 61-74-5

| CAS_supplemental =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 5C0K1GQB2L

| ATC_prefix = None

| ATC_suffix =

| ChEMBL = 2105038

| PubChem = 208853

| ChemSpiderID = 180960

| C = 16 | H = 18 | N = 2 | O = 2

| smiles = O1c3c(OC(C1)CN(N)Cc2ccccc2)cccc3

| StdInChI = 1S/C16H18N2O2/c17-18(10-13-6-2-1-3-7-13)11-14-12-19-15-8-4-5-9-16(15)20-14/h1-9,14H,10-12,17H2

| StdInChIKey = IXTXYSAWZICAPV-UHFFFAOYSA-N

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_category =

| legal_status =

| routes_of_administration =

}}

Domoxin (INN) is a hydrazine derivative monoamine oxidase inhibitor (MAOI) antidepressant which was never marketed.{{cite web | url =https://www.who.int/medicines/services/inn/StemBook_2011_Final.pdf | author = World Health Organization | title = The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances | year = 2011 | accessdate = 2012-05-20}}